

Monoclonal Anti-Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Protein, Clone 5F7 (produced *in vitro*)

Catalog No. HRP-2533
NIBSC Catalog No. 3013

For research use only. Not for use in humans.

Contributor:

Dr. Albrecht von Brunn, Principal Investigator, Max von Pettenkofer Institute and Gene Center, Ludwig-Maximilians-Universität, Munich, Germany

Manufacturer:

Centre for AIDS Reagents, National Institute for Biological Standards and Control (NIBSC), United Kingdom

Product Description:

Antibody Class: IgG1
HRP-2533 is a monoclonal antibody to human immunodeficiency virus type 1 (HIV-1) gp120, specifically the V3 loop (epitope: RIQRGPGRAFVTIGK).¹ This antibody (available as NIBSC Cat. No. 3013) originates from a hybridoma created by immunizing BALB/c mice with HIV-1 gp120 (residues 308 to 322) fused to hepatitis B core antigen (HBcAg) particles. The resulting splenocytes were fused to Ag8653 myeloma cells. The antibody inhibits syncytium formation, reverse transcriptase activity, and p24 production *in vitro* (partial inhibition and retardation over 20 days).

Material Provided:

Each vial contains approximately 200 µL of cell culture supernatant.

Packaging/Storage:

HRP-2533 was packaged aseptically in cryovials. The product is provided frozen on dry ice and should be stored at -20°C or colder immediately upon arrival. Freeze thaw cycles should be avoided.

Functional Activity:

HRP-2533 recognizes HIV-1 LAI gp160 and the V3 peptide RIQRGPGRAFVTIGK (residues 308 to 322) in ELISA. It also reacts in western blot with gp120 (LAI) and in immunofluorescence assay with HIV-1 LAI-infected H9 cells.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH and Centre for AIDS Reagents, NIBSC, UK, supported by EURIPRED (EC FP7 INFRASTRUCTURES-2012 - INFRA-2012-1.1.5: Grant Number 31266): Monoclonal Anti-Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Protein, Clone 5F7 (produced *in vitro*), HRP-2533."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. von Brunn, A., et al. "Principal Neutralizing Domain of HIV-1 is Highly Immunogenic When Expressed on the Surface of Hepatitis B Core Particles." *Vaccine* 11 (1993): 817-824. PubMed: 7689283.

ATCC® is a trademark of the American Type Culture Collection.

